Fluorinated Pyrimidine Compounds for Resistant HIV Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV treatments face challenges with the emergence of drug-resistant HIV variants and the need for compounds with improved potency, metabolic stability, and pharmacokinetic/pharmacodynamic profiles to effectively treat Retroviridae viral infections.
Innovation Solution
Development of novel compounds, such as those represented by formulas (Ia), (Ib), (IIa), and (IIb), which exhibit enhanced potency, metabolic stability, and pharmacokinetic/pharmacodynamic profiles, potentially allowing for less frequent dosing regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HAART treatments are used, then viral load is reduced and disease progression is delayed, but drug-resistant HIV variants emerge
Solution Approach 1:
The patent modifies the chemical structure of reverse transcriptase inhibitors by changing parameters such as introducing fluorine atoms at specific positions (e.g., position 2 of the pyrimidine ring), adjusting molecular weight, and modifying pharmacokinetic properties to achieve enhanced potency and reduced resistance development compared to conventional HAART drugs
Solution Approach 2:
The invention creates composite molecular structures combining multiple functional groups (e.g., pyrimidine core with fluorinated aromatic substituents and specific side chains) to achieve both high antiviral activity and optimized pharmacokinetic profiles that prevent resistance emergence
2Reliability
If treatment efficacy is improved, then drug-resistant variants are suppressed, but dosing frequency may need to increase
Solution Approach 1:
The patent optimizes pharmacokinetic parameters by adjusting molecular properties (e.g., lipophilicity, molecular weight, and metabolic stability) to achieve extended half-life and improved bioavailability, allowing for reduced dosing frequency while maintaining high potency against resistant HIV variants
3Reliability
If compound potency is increased, then treatment effectiveness improves, but metabolic stability may deteriorate
Solution Approach 1:
The invention introduces fluorine atoms at specific positions in the molecular structure (e.g., position 2 of the pyrimidine ring and specific aromatic positions) to enhance both antiviral potency and metabolic stability by reducing enzymatic degradation while maintaining high binding affinity to the viral reverse transcriptase enzyme
Data Source
AI summary
The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb):which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.